Month: January 2024

Jan 02 2024

Uncategorized

BMS wagers $14bn on Karuna’s schizophrenia drug

by Clinical Editor

No Comments

BMS’ move for Karuna comes a few weeks after AbbVie agreed an $8.7 billion deal to acquire Cerevel Therapeutics, another company developing a schizophrenia drug with a novel mechanism of...

Jan 01 2024

Uncategorized

Texas veteran who battled schizophrenia drowns in Lake Huron – Huron Daily Tribune

by Clinical Editor

No Comments

Texas veteran who battled schizophrenia drowns in Lake Huron  Huron Daily Tribune

Jan 01 2024

Uncategorized

Study finds ED visits for schizophrenia spectrum disorders up after pandemic onset

by Clinical Editor

No Comments

The number of emergency department visits for schizophrenia spectrum disorders increased after the onset of the COVID-19 pandemic, according to a study published online Dec. 27 in JAMA Network Open.

Jan 01 2024

Uncategorized

A new approach to schizophrenia keeps young people in school, but insurance won’t pay

by Clinical Editor

No Comments

A new approach to schizophrenia involves managing early psychosis symptoms and keeping young people in school or jobs. The treatment is effective, but private insurance plans usually won’t cover it.

Jan 01 2024

Uncategorized

Could Being Around Cats In Childhood Have A Link To Schizophrenia? Here’s What A Study Found

by Clinical Editor

No Comments

Infection from the toxoplasma gondii parasite found in cat feces and undercooked red meat is understood to have links to many unusual things, including mental illnesses.

Jan 01 2024

Uncategorized

Growing Up With Cats Linked to Higher Schizophrenia Risk

by Clinical Editor

No Comments

Scientists found that childhood cat ownership is associated with developing schizophrenia—a risk possibly fueled by a parasite.

Jan 01 2024

Uncategorized

Leaning toward big wins in schizophrenia and vaccines, venture group raises new fund of $389 million

by Clinical Editor

No Comments

Pivotal BioVenture Partners, an early investor in schizophrenia drug developer Karuna, vaccine maker Vaxcyte, has raised a second fund of $389 million. It’s a vote of confidence for the troubled...